Standex International Corporation announced Samantha L. Stoddard will become its Vice President, Chief Financial Officer, and Treasurer effective December 1, 2026. She joins from JELD-WEN Holding, where she was Executive Vice President and CFO. Stoddard will replace Ademir Sarcevic, who will focus on growing Standex's Electronics segment after her arrival. This leadership change aims to support Standex's growth strategy and operational excellence across its diversified manufacturing businesses.
Standex International's CFO appointment news provides context for readers following industrial stocks. For readers following Industrials-sector US stocks on Pluang, here is the market snapshot as of Oct 20, 2026 03:01 WIB: out of 135 priced stocks, 46 rose and 88 fell. Notable movers include TE (T1 Energy Inc. Common Stock) at USD 2.53 with a 1-day change of -3.44% and a typical hold time of 5 days, CHRW (C.H. Robinson Worldwide, Inc.) at USD 144.20 with a 1-day change of +3.41% and a typical hold time of 28 days, and FRO (Frontline Plc Ordinary Shares) at USD 50.71 with a 1-day change of -3.39%, a typical hold time of 4 days, and Pluang order activity showing 0% Sell / 100% Buy.
The Hershey Trust Company sold 1,512 common shares under a trading plan but kept voting control through Class B shares. Hershey will report Q3 earnings on October 29, with investors focused on how price increases affected Halloween-season demand. Q2 ...
W. R. Berkley reported mixed Q3 2026 results with earnings per share of $1.17 beating estimates, but revenue fell short at $3.74 billion versus $3.82 billion expected. The company saw premium growth with gross premiums up 3% and net premiums up 1%, s...
GE Aerospace is set to report its Q3 earnings with analysts forecasting a 21.7% rise in earnings per share to $2.02 and nearly 12% revenue growth to about $12.7 billion. Despite consistently beating estimates, the stock has fallen after past reports ...
Silence Therapeutics' stock surged 125.6% to $19.58 following Merck KGaA's agreement to acquire the RNA-interference drug developer for about $1.3 billion in equity value. Merck will pay $20 per share, a 130% premium over the recent closing price. Ot...
On October 19, 2026, several stocks saw significant declines. Iambic Therapeutics dropped 31.4% but stayed just above its IPO price of $16 after raising $150 million. TCGX Acquisition fell 18.5% following its announcement of a merger with TriGemX Bio...
